Reference is made to the Annual General Meeting in Aker BioMarine held on 20
April 2022 in which Mr. Øyvind Eriksen was appointed as deputy member to the
Board of Directors. The Board of Directors has on 8 June 2022 appointed Mr.
Eriksen as an observer to the Board. Mr. Eriksen will consequently resign as
deputy member.


For further information, please contact 
Carl Christian Bachke, Investor Relations
Mobile: +47 909 808 48
Email: carl.bachke@akerbiomarine.com  

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for pharma, consumer health and
wellness as well as animal nutrition. The company has a strong position in its
industry and is the world's leading supplier of krill, the natural, powerful and
health promoting source of nutrients from the pristine waters of Antarctica.
Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is
available at www.akerbiomarine.com.

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange